Biogen (BIIB)
(Real Time Quote from BATS)
$144.36 USD
-0.51 (-0.35%)
Updated Sep 18, 2025 10:34 AM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Biogen Inc. has a PEG ratio of 1.13 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.64.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIIB 144.36 -0.51(-0.35%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Biogen Gets EU Nod for First Postpartum Depression Drug
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
Other News for BIIB
M&A News: Biotech Biogen Buys Alcyone Therapeutics for $85M to Boost Brain Treatments
Biogen to buy Massachusetts-based Alcyone Therapeutics
The technical outlook for BIIB is unchanged after it rises 0.83% on September 17
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Drug Delivery System
Biogen to acquire Alcyone Therapeutics for $85M upfront cash payment